Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -110% Improvement Relative Risk Hospitalization, COVID-19 58% Hospitalization, all cause 53% c19early.org/m Goodwin et al. Molnupiravir for COVID-19 EARLY Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 416 patients in the United Kingdom (Dec 2021 - Feb 2022) Study underpowered to detect differences Goodwin et al., PLOS ONE, doi:10.1371/journal.pone.0281915 Favors molnupiravir Favors control
Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional centre in the UK
Goodwin et al., PLOS ONE, doi:10.1371/journal.pone.0281915
Goodwin et al., Evaluation of outpatient treatment for non-hospitalised patients with COVID-19: The experience of a regional.., PLOS ONE, doi:10.1371/journal.pone.0281915
Mar 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 604 outpatients in the UK, showing lower risk of hospitalization with molnupiravir treatment, without statistical significance due to the small number of hospitalizations.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [Fountain-Jones, Sanderson, twitter.com] for analysis of variants potentially created by molnupiravir.
risk of death, 110.0% higher, RR 2.10, p = 0.47, treatment 1 of 80 (1.2%), control 2 of 336 (0.6%).
risk of hospitalization, 58.0% lower, RR 0.42, p = 0.70, treatment 1 of 80 (1.2%), control 10 of 336 (3.0%), NNT 58, COVID-19 related.
risk of hospitalization, 53.3% lower, RR 0.47, p = 0.39, treatment 2 of 80 (2.5%), control 18 of 336 (5.4%), NNT 35, all cause.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Goodwin et al., 15 Mar 2023, retrospective, United Kingdom, peer-reviewed, 3 authors, study period 22 December, 2021 - 20 February, 2022.
Contact: amanda.goodwin@nottingham.ac.uk.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Abstract: PLOS ONE RESEARCH ARTICLE Evaluation of outpatient treatment for nonhospitalised patients with COVID-19: The experience of a regional centre in the UK Amanda T. Goodwin ID1*, Jonathan S. Thompson2, Ian P. Hall1 1 NIHR Nottingham Biomedical Research Centre & University of Nottingham, Nottingham, United Kingdom, 2 Department of Infectious Diseases, Nottingham University Hospitals, Nottingham, United Kingdom * Amanda.Goodwin@nottingham.ac.uk a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 OPEN ACCESS Citation: Goodwin AT, Thompson JS, Hall IP (2023) Evaluation of outpatient treatment for nonhospitalised patients with COVID-19: The experience of a regional centre in the UK. PLoS ONE 18(3): e0281915. https://doi.org/10.1371/ journal.pone.0281915 Editor: Seung-Hwa Lee, Samsung Medical Center, REPUBLIC OF KOREA Received: July 18, 2022 Accepted: February 5, 2023 Published: March 15, 2023 Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0281915 Copyright: © 2023 Goodwin et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Abstract
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit